Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are
progressively becoming the standard of care in the treatment of many tumour types …

ICI-associated irAEs constitute a new group of neurologic complications of systemic
anticancer therapies. Although potentially severe, these rare neurologic toxicities are often …

Importance Neurological complications are an increasingly recognized consequence of the
use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors …

Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various
cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated …

Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …

Neuromuscular adverse events following cancer treatment with anti-programmed cell death
protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We …

Immunotherapy has an increasing role in the management of cancer, both in metastatic
disease and as an adjuvant therapy. However, sensitization of the immune system with …

Identification and characterization of T-cell regulatory mechanisms, or checkpoints, have led
to a wave of drug development aimed at inhibiting these targets to “remove the brakes” of …

Abstract Purpose of Review In recent years, immune checkpoint inhibitors have been
increasingly used in patients with metastatic cancers with favorable oncological outcomes; …

Immune checkpoint inhibitors (ICIs) are increasingly used and are becoming the standard of
care in the treatment of various tumor types. Despite the favorable results in terms of …